查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1855943

PD-L1 和 PIK3CA 檢測全球市場報告（2025 年）

PD-L1 And PIK3CA Testing Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，PD-L1和PIK3CA檢測的市場規模迅速擴張，從2024年的14.5億美元成長到2025年的16.7億美元，複合年成長率達15.6%。這一成長主要歸因於再生醫學臨床試驗的增加、對個人化醫療的日益重視、產學研合作的加強、人們對細胞療法的療效和安全性認知的提高，以及CAR-T療法和其他自體細胞療法的首次核准帶來的快速成長。

預計未來幾年，PD-L1 和 PIK3CA 檢測市場將快速成長，到 2029 年市場規模將達到 29.6 億美元，複合年成長率 (CAGR) 為 15.3%。預測期內的成長可歸因於個人化和精準醫療的廣泛應用、細胞和基因治療產品線的不斷擴展、臨床試驗和商業核准數量的增加、再生醫學投資的成長以及慢性病和罕見患者病率的上升。預測期內的關鍵趨勢包括：生物資訊學在細胞研究中的發展、細胞治療追蹤與數位健康平台的整合、人工智慧和機器學習應用的興起、雲端基礎的創新以及穿戴式生物感測器的應用。

癌症發生率的不斷上升預計將推動PD-L1和PIK3CA檢測市場的擴張。癌症的特徵是異常細胞不受控制地生長和擴散，由於生活方式相關風​​險和人口老化等因素，癌症的發生率正在上升。這些因素導致診斷率上升，並刺激了對早期檢測和有效治療方案的需求。 PD-L1和PIK3CA檢測透過提供準確的診斷、實現個人化治療以及指導標靶治療來改善臨床療效，有助於癌症管理。例如，美國癌症協會在2024年9月預測，全球男性癌症患者人數將顯著增加，預計從2022年的1,030萬增至2029年的1,900萬，增幅達84%。癌症患者的快速成長正在推動PD-L1和PIK3CA檢測市場的成長。

PD-L1 和 PIK3CA 檢測市場的主要企業正致力於技術進步，特別是伴隨診斷的整合，以改善治療標靶性並提高癌症治療的療效。伴隨診斷整合是指將先進的檢測系統與標靶藥物協同設計，根據患者的生物標記譜識別最有可能從特定治療中獲益的病患小組。例如，2024 年 10 月，總部位於瑞士的生物技術和製藥公司羅氏宣布，Itobevi（inavolisib）聯合Palbociclib和 fulvestrant 用於治療內分泌抗藥性、PIK3CA 突變、HR 陽性、HER2 陰性的晚期或轉移性乳癌患者。 FDA 基於 III 期 INAVO120 試驗核准了該方案，該試驗表明，與Palbociclib和 fulvestrant 單藥治療相比，該方案的無惡化生存期延長了一倍以上。這是羅氏首個針對 HR 陽性患者的分子標靶治療方法，並包含伴隨診斷，用於識別符合條件的患者，這標誌著精準醫療在治療選擇有限的患者群體中取得了重大進展。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅，以及新冠疫情及其復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球PD-L1和PIK3CA檢測：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 終端用戶產業分析
  • 全球PD-L1和PIK3CA檢測市場：成長率分析
  • 全球PD-L1和PIK3CA檢測市場表現：規模和成長，2019-2024年
  • 全球PD-L1和PIK3CA檢測市場預測：規模和成長，2024-2029年，2034年
  • 全球PD-L1和PIK3CA檢測：潛在市場規模（TAM）

第6章 市場細分

  • 全球PD-L1和PIK3CA檢測市場按檢測類型、效能和預測分類，2019-2024年、2024-2029年、2034年
  • 免疫組織化學
  • 次世代定序
  • 聚合酵素鏈鎖反應
  • 其他測試類型
  • 全球PD-L1和PIK3CA檢測市場按樣品類型、性能和預測分類，2019-2024年、2024-2029年、2034年
  • 組織樣本
  • 液體切片檢查樣本
  • 全球PD-L1和PIK3CA檢測市場按分銷管道分類：實際數據和預測，2019-2024年、2024-2029年、2034年
  • 直銷
  • 經銷商和經銷商
  • 線上銷售平台
  • 全球PD-L1和PIK3CA檢測市場按應用、效能和預測分類，2019-2024年、2024-2029年、2034年
  • 癌症診斷
  • 藥物研發
  • 研究
  • 其他用途
  • 全球PD-L1和PIK3CA檢測市場按最終用戶、效能和預測分類，2019-2024年、2024-2029年、2034年
  • 醫院和診所
  • 研究所
  • 製藥公司
  • 全球PD-L1和PIK3CA檢測市場：按免疫組化、類型、性能和預測進行細分，2019-2024年、2024-2029年、2034年
  • 組織染色
  • 蛋白質表現分析
  • 腫瘤微環境評估
  • 全球PD-L1和PIK3CA檢測市場：依次世代定序、類型、效能和預測進行細分，2019-2024年、2024-2029年、2034年
  • 全基因組定序
  • 標靶基因定序
  • EXOME定序
  • 核糖核酸（RNA）定序
  • 全球PD-L1和PIK3CA檢測市場：聚合酵素鏈鎖反應、類型、性能和預測進行細分，2019-2024年、2024-2029年、2034年
  • 定量聚合酵素鏈鎖反應
  • 逆轉錄聚合酵素鏈鎖反應
  • 數位聚合酵素鏈鎖反應
  • 全球PD-L1和PIK3CA檢測市場：按檢測類型、其他檢測類型、類型、性能和預測進行細分，2019-2024年、2024-2029年、2034年
  • 原位雜合反應（ISH）
  • 桑格定序
  • 流式細胞技術
  • 基於微陣列的偵測

第7章 區域和國家分析

  • 全球PD-L1及PIK3CA檢測市場：區域表現及預測，2019-2024年、2024-2029年及2034年
  • 全球PD-L1和PIK3CA檢測市場：國家、效能與預測，2019-2024年、2024-2029年、2034年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章：西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章 俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • PD-L1 與 PIK3CA 檢測市場：競爭格局
  • PD-L1 和 PIK3CA 檢測市場：公司概況
    • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Laboratory Corporation of America Holdings（Labcorp）Overview, Products and Services, Strategy and Financial Analysis
    • Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Eurofins Scientific SE
  • Agilent Technologies Inc.
  • Sonic Healthcare Limited
  • Illumina Inc.
  • Bio-Rad Laboratories Inc.
  • QIAGEN NV
  • Myriad Genetics Inc.
  • NeoGenomics Laboratories Inc.
  • BGI Genomics Co. Ltd.
  • Guardant Health Inc.
  • Caris Life Sciences
  • Foundation Medicine Inc.
  • Amoy Diagnostics Co. Ltd.
  • ACCB Biotech Private Limited
  • EntroGen Inc.

第32章 全球市場競爭基準化分析與儀錶板

第33章 重大併購

第34章 近期市場趨勢

第35章：高潛力市場國家、細分市場與策略

  • 2029年PD-L1和PIK3CA檢測市場：提供新機會的國家
  • PD-L1 和 PIK3CA 檢測市場 2029：充滿新機會的細分市場
  • PD-L1 和 PIK3CA 檢測市場 2029 年：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章附錄

簡介目錄
Product Code: r38595

PD-L1 and PIK3CA testing are molecular diagnostic methods used to identify specific biomarkers that support targeted cancer treatment decisions. PD-L1 testing measures the expression of the programmed death ligand 1 protein on tumor cells to evaluate the likelihood of response to immunotherapies. PIK3CA testing identifies mutations in the phosphatidylinositol 4,5 bisphosphate 3 kinase catalytic subunit alpha gene, which helps determine eligibility for therapies directed at the PI3K pathway.

The primary test types of PD-L1 and PIK3CA testing include immunohistochemistry, next generation sequencing, polymerase chain reaction, and others. Immunohistochemistry is a laboratory method that applies antibodies to detect specific proteins in tissue samples, making it possible to visualize their location and concentration under a microscope. The sample types used are tissue samples and liquid biopsy samples. The distribution channels include direct sales, distributors and resellers, and online sales platforms. The applications involve cancer diagnosis, drug development, research, and other uses, and they serve multiple end users such as hospitals and clinics, laboratories, and pharmaceutical companies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers' margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The PD-L1 and PIK3CA testing market research report is one of a series of new reports from The Business Research Company that provides PD-L1 and PIK3CA testing market statistics, including the PD-L1 and PIK3CA testing industry global market size, regional shares, competitors with the PD-L1 and PIK3CA testing market share, detailed PD-L1 and PIK3CA testing market segments, market trends, and opportunities, and any further data you may need to thrive in the PD-L1 and PIK3CA testing industry. This PD-L1 and PIK3CA testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The PD-L1 and PIK3CA testing market size has grown rapidly in recent years. It will grow from $1.45 billion in 2024 to $1.67 billion in 2025 at a compound annual growth rate (CAGR) of 15.6%. The growth during the historic period can be linked to the rise in clinical trials for regenerative medicine, increasing emphasis on personalized medicine, expansion of collaborations between academia and industry, greater awareness of the efficacy and safety of cell therapies, and rapid growth with the first approvals of CAR T and other autologous cell therapies.

The PD-L1 and PIK3CA testing market size is expected to see rapid growth in the next few years. It will grow to $2.96 billion in 2029 at a compound annual growth rate (CAGR) of 15.3%. The growth during the forecast period can be attributed to the wider adoption of personalized and precision medicine, expansion of the pipeline for cell and gene therapies, increase in clinical trials and commercial approvals, rising investment in regenerative medicine, and higher incidence of chronic and rare diseases. Key trends in the forecast period include the development of bioinformatics in cellular research, integration of cell therapy tracking with digital health platforms, advancement of artificial intelligence and machine learning applications, innovation in cloud based data management systems, and adoption of wearable biosensors.

The growing prevalence of cancer is expected to drive the expansion of the PD-L1 and PIK3CA testing market. Cancer, which is characterized by the uncontrolled growth and spread of abnormal cells, has become more common due to factors such as lifestyle-related risks and an aging population. These factors contribute to higher diagnosis rates and an increased demand for early detection and effective treatment solutions. PD-L1 and PIK3CA testing help manage cancer by providing accurate diagnoses and guiding targeted therapies, which allow treatments to be personalized to individual patients and improve clinical outcomes. For example, in September 2024, the American Cancer Society projected a significant increase in global cancer cases among men, estimating an 84% rise by 2029, from 10.3 million in 2022 to 19 million. This surge in cancer cases is driving the growth of the PD-L1 and PIK3CA testing market.

Key players in the PD-L1 and PIK3CA testing market are focusing on technological advancements, particularly the integration of companion diagnostics, to improve therapeutic targeting and enhance treatment efficacy in oncology. Companion diagnostic integration involves advanced testing systems designed alongside targeted medicines to identify patient groups most likely to benefit from specific treatments based on biomarker profiles. For instance, in October 2024, F. Hoffmann-La Roche AG, a Switzerland-based biotechnology and pharmaceutical company, introduced Itovebi (inavolisib) in combination with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer. The FDA approved this regimen based on the Phase III INAVO120 study, which showed more than double the progression-free survival compared to palbociclib and fulvestrant alone. This marks Roche's first targeted therapy for HR-positive disease and incorporates a companion diagnostic to identify eligible patients, representing a major step forward in precision medicine for a patient population with limited treatment options.

In December 2022, Prenetics Global Limited, a Hong Kong-based health technology company, acquired ACT Genomics Co. Ltd. for an undisclosed amount. With this acquisition, Prenetics aims to strengthen its position in the precision oncology market by incorporating ACT Genomics' advanced capabilities in next-generation sequencing (NGS), bioinformatics, and comprehensive genomic profiling. ACT Genomics, based in Taiwan, is a molecular diagnostics company that provides PD-L1 and PIK3CA biomarker testing to guide cancer treatment.

Major players in the PD-L1 and PIK3CA testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Sonic Healthcare Limited, Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., NeoGenomics Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences, Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., ACCB Biotech Private Limited, EntroGen Inc.

North America was the largest region in the PD-L1 and PIK3CA testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in PD-L1 and PIK3CA testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the PD-L1 and PIK3CA testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The PD-L1 and PIK3CA testing market includes revenues earned by entities through the biomarker testing, molecular diagnostics, genetic mutation detection, generation sequencing services, companion diagnostic testing, pathology interpretation, and clinical trial testing support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

PD-L1 And PIK3CA Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pd-l1 and pik3ca testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pd-l1 and pik3ca testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pd-l1 and pik3ca testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Test Type: Immunohistochemistry; Next-Generation Sequencing; Polymerase Chain Reaction; Other Test Types
  • 2) By Sample Type: Tissue Samples; Liquid Biopsy Samples
  • 3) By Distribution Channel: Direct Sales; Distributors And Resellers; Online Sales Platforms
  • 4) By Applications: Cancer Diagnosis; Drug Development; Research; Other Applications
  • 5) By End User: Hospitals And Clinics; Laboratories; Pharmaceutical Companies
  • Subsegments:
  • 1) By Immunohistochemistry: Tissue Staining; Protein Expression Analysis; Tumor Microenvironment Assessment
  • 2) By Next-Generation Sequencing: Whole Genome Sequencing; Targeted Gene Sequencing; Exome Sequencing; Ribonucleic Acid (RNA) Sequencing
  • 3) By Polymerase Chain Reaction: Quantitative Polymerase Chain Reaction; Reverse Transcription Polymerase Chain Reaction; Digital Polymerase Chain Reaction
  • 4) By Other Test Types: In Situ Hybridization (ISH); Sanger Sequencing; Flow Cytometry; Microarray-Based Assays
  • Companies Mentioned: F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc.; Abbott Laboratories; Laboratory Corporation of America Holdings (Labcorp); Quest Diagnostics Incorporated; Eurofins Scientific SE; Agilent Technologies Inc.; Sonic Healthcare Limited; Illumina Inc.; Bio-Rad Laboratories Inc.; QIAGEN N.V.; Myriad Genetics Inc.; NeoGenomics Laboratories Inc.; BGI Genomics Co. Ltd.; Guardant Health Inc.; Caris Life Sciences; Foundation Medicine Inc.; Amoy Diagnostics Co. Ltd.; ACCB Biotech Private Limited; EntroGen Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. PD-L1 And PIK3CA Testing Market Characteristics

3. PD-L1 And PIK3CA Testing Market Trends And Strategies

4. PD-L1 And PIK3CA Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global PD-L1 And PIK3CA Testing Growth Analysis And Strategic Analysis Framework

  • 5.1. Global PD-L1 And PIK3CA Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global PD-L1 And PIK3CA Testing Market Growth Rate Analysis
  • 5.4. Global PD-L1 And PIK3CA Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global PD-L1 And PIK3CA Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global PD-L1 And PIK3CA Testing Total Addressable Market (TAM)

6. PD-L1 And PIK3CA Testing Market Segmentation

  • 6.1. Global PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immunohistochemistry
  • Next-Generation Sequencing
  • Polymerase Chain Reaction
  • Other Test Types
  • 6.2. Global PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Tissue Samples
  • Liquid Biopsy Samples
  • 6.3. Global PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Direct Sales
  • Distributors And Resellers
  • Online Sales Platforms
  • 6.4. Global PD-L1 And PIK3CA Testing Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cancer Diagnosis
  • Drug Development
  • Research
  • Other Applications
  • 6.5. Global PD-L1 And PIK3CA Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals And Clinics
  • Laboratories
  • Pharmaceutical Companies
  • 6.6. Global PD-L1 And PIK3CA Testing Market, Sub-Segmentation Of Immunohistochemistry, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Tissue Staining
  • Protein Expression Analysis
  • Tumor Microenvironment Assessment
  • 6.7. Global PD-L1 And PIK3CA Testing Market, Sub-Segmentation Of Next-Generation Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Whole Genome Sequencing
  • Targeted Gene Sequencing
  • Exome Sequencing
  • Ribonucleic Acid (RNA) Sequencing
  • 6.8. Global PD-L1 And PIK3CA Testing Market, Sub-Segmentation Of Polymerase Chain Reaction, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Quantitative Polymerase Chain Reaction
  • Reverse Transcription Polymerase Chain Reaction
  • Digital Polymerase Chain Reaction
  • 6.9. Global PD-L1 And PIK3CA Testing Market, Sub-Segmentation Of Other Test Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • In Situ Hybridization (ISH)
  • Sanger Sequencing
  • Flow Cytometry
  • Microarray-Based Assays

7. PD-L1 And PIK3CA Testing Market Regional And Country Analysis

  • 7.1. Global PD-L1 And PIK3CA Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global PD-L1 And PIK3CA Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific PD-L1 And PIK3CA Testing Market

  • 8.1. Asia-Pacific PD-L1 And PIK3CA Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China PD-L1 And PIK3CA Testing Market

  • 9.1. China PD-L1 And PIK3CA Testing Market Overview
  • 9.2. China PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India PD-L1 And PIK3CA Testing Market

  • 10.1. India PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan PD-L1 And PIK3CA Testing Market

  • 11.1. Japan PD-L1 And PIK3CA Testing Market Overview
  • 11.2. Japan PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia PD-L1 And PIK3CA Testing Market

  • 12.1. Australia PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia PD-L1 And PIK3CA Testing Market

  • 13.1. Indonesia PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea PD-L1 And PIK3CA Testing Market

  • 14.1. South Korea PD-L1 And PIK3CA Testing Market Overview
  • 14.2. South Korea PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe PD-L1 And PIK3CA Testing Market

  • 15.1. Western Europe PD-L1 And PIK3CA Testing Market Overview
  • 15.2. Western Europe PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK PD-L1 And PIK3CA Testing Market

  • 16.1. UK PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany PD-L1 And PIK3CA Testing Market

  • 17.1. Germany PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France PD-L1 And PIK3CA Testing Market

  • 18.1. France PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy PD-L1 And PIK3CA Testing Market

  • 19.1. Italy PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain PD-L1 And PIK3CA Testing Market

  • 20.1. Spain PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe PD-L1 And PIK3CA Testing Market

  • 21.1. Eastern Europe PD-L1 And PIK3CA Testing Market Overview
  • 21.2. Eastern Europe PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia PD-L1 And PIK3CA Testing Market

  • 22.1. Russia PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America PD-L1 And PIK3CA Testing Market

  • 23.1. North America PD-L1 And PIK3CA Testing Market Overview
  • 23.2. North America PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA PD-L1 And PIK3CA Testing Market

  • 24.1. USA PD-L1 And PIK3CA Testing Market Overview
  • 24.2. USA PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada PD-L1 And PIK3CA Testing Market

  • 25.1. Canada PD-L1 And PIK3CA Testing Market Overview
  • 25.2. Canada PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America PD-L1 And PIK3CA Testing Market

  • 26.1. South America PD-L1 And PIK3CA Testing Market Overview
  • 26.2. South America PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil PD-L1 And PIK3CA Testing Market

  • 27.1. Brazil PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East PD-L1 And PIK3CA Testing Market

  • 28.1. Middle East PD-L1 And PIK3CA Testing Market Overview
  • 28.2. Middle East PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa PD-L1 And PIK3CA Testing Market

  • 29.1. Africa PD-L1 And PIK3CA Testing Market Overview
  • 29.2. Africa PD-L1 And PIK3CA Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa PD-L1 And PIK3CA Testing Market, Segmentation By Sample Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa PD-L1 And PIK3CA Testing Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. PD-L1 And PIK3CA Testing Market Competitive Landscape And Company Profiles

  • 30.1. PD-L1 And PIK3CA Testing Market Competitive Landscape
  • 30.2. PD-L1 And PIK3CA Testing Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Laboratory Corporation of America Holdings (Labcorp) Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis

31. PD-L1 And PIK3CA Testing Market Other Major And Innovative Companies

  • 31.1. Eurofins Scientific SE
  • 31.2. Agilent Technologies Inc.
  • 31.3. Sonic Healthcare Limited
  • 31.4. Illumina Inc.
  • 31.5. Bio-Rad Laboratories Inc.
  • 31.6. QIAGEN N.V.
  • 31.7. Myriad Genetics Inc.
  • 31.8. NeoGenomics Laboratories Inc.
  • 31.9. BGI Genomics Co. Ltd.
  • 31.10. Guardant Health Inc.
  • 31.11. Caris Life Sciences
  • 31.12. Foundation Medicine Inc.
  • 31.13. Amoy Diagnostics Co. Ltd.
  • 31.14. ACCB Biotech Private Limited
  • 31.15. EntroGen Inc.

32. Global PD-L1 And PIK3CA Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The PD-L1 And PIK3CA Testing Market

34. Recent Developments In The PD-L1 And PIK3CA Testing Market

35. PD-L1 And PIK3CA Testing Market High Potential Countries, Segments and Strategies

  • 35.1 PD-L1 And PIK3CA Testing Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 PD-L1 And PIK3CA Testing Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 PD-L1 And PIK3CA Testing Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer